Schizophrenia Treatments: Antipsychotics and CBT
This paper examines the range of treatments available for schizophrenia, a brain disorder affecting approximately 21 million people worldwide. It reviews pharmacological approaches—particularly antipsychotic neuroleptics and polypharmacy strategies—alongside therapeutic interventions such as cognitive behavioral therapy (CBT), support group therapy, and psychosocial methods. Drawing on clinical research, guidelines from the American Psychiatric Association, and patient accounts, the paper argues that combining neuroleptics with CBT represents the most evidence-supported approach. It also addresses the limitations of this preferred treatment, the importance of patient rights and consent, and the need for individualized, collaborative care planning among providers, patients, and families.
- Introduction to Schizophrenia and Its Symptoms: Definition, diagnosis criteria, and global prevalence
- Available Treatments Overview: Pharmacological and therapeutic treatment options reviewed
- Preferred Treatment: Neuroleptics Combined with CBT: Case for combining antipsychotics with behavioral therapy
- Limitations of the Preferred Treatment: Constraints of neuroleptic-CBT approach and alternatives
- Conclusion: Summary of treatment goals and patient-centered care
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Integrates multiple types of evidence — large-scale meta-analyses, clinical guidelines, and first-person patient accounts — to build a well-rounded argument for a preferred treatment protocol.
- Balances clinical recommendations with ethical considerations, consistently returning to the importance of patient autonomy and informed consent throughout the treatment process.
- Acknowledges the limitations of the preferred treatment honestly rather than overstating its efficacy, which strengthens the paper's overall credibility.
Key academic technique demonstrated
The paper demonstrates effective synthesis of secondary sources. Rather than simply summarizing each study in turn, the author weaves findings from Leucht et al. (2013), Turkington et al. (2002), and Zink et al. (2010) into a coherent argument for a combined pharmacological-therapeutic approach. The use of Elyn Saks' first-person account as both supporting evidence and a humanizing frame is a particularly strong rhetorical move that bridges clinical literature and lived experience.
Structure breakdown
The paper opens with a definition and epidemiological context for schizophrenia, then surveys the full range of treatment options before narrowing to argue for a preferred combination. A dedicated section on the limitations of that preferred approach prevents the argument from feeling one-sided. The conclusion restates the core thesis and emphasizes the collaborative, patient-centered model of care. This funnel structure — broad overview to specific recommendation to honest qualification — is a reliable and effective organizational pattern for clinical topic papers.
Introduction to Schizophrenia and Its Symptoms
Schizophrenia is a brain disorder that results in hallucinations, paranoid delusions, confused or disordered thinking and/or speech, difficulty concentrating and functioning, and other negative symptoms. It is diagnosed according to criteria described by the Diagnostic and Statistical Manual of Mental Disorders (DSM-V, 2013): the individual must show signs of hallucinations, delusions, or disorganized speech in a continuous manner for at least six months, with at least one month of active symptoms occurring that negatively impacts the person's ability to work or socialize consistently. The World Health Organization (2017) states that roughly 21 million people throughout the world suffer from schizophrenia. Schizophrenia is a treatable disease, however, and as Saks (2009) shows, an individual can lead a normal life while having schizophrenia because there are a number of treatments available to help control the symptoms.
Available Treatments Overview
Treatments available for individuals who suffer from schizophrenia typically include a combination of pharmacological approaches and therapeutic approaches. Pharmacological treatments include antipsychotic mood stabilizers called neuroleptics. Therapeutic interventions include a wide range of methods, such as support group therapy or psychosocial therapy. Dietary supplements like glycine are also utilized alongside mood stabilizers or antidepressants. In extreme cases, electroconvulsive therapy has been used to stabilize individuals who suffer from schizophrenia (Kates, Dequardo, & Tandon, 1999).
Antipsychotics, or neuroleptics, are commonly used to treat schizophrenia and typically result in a reduction of the positive symptoms of the disease. There are a variety of drug choices available, as Leucht, Cipriani, Spineli et al. (2013) showed in their comparative study of 15 antipsychotic drugs used to treat schizophrenia. Their meta-analysis of 212 suitable trials, including data from over 43,000 patients, showed that all fifteen drugs "were significantly more effective than placebo" (Leucht et al., 2013, p. 951). Drugs can differ in terms of the side effects they cause, so finding the right drug for the patient can sometimes be a process of trial and error, as much of the pharmacological success of this treatment depends on how the individual responds to the drug. Nonetheless, neuroleptics are viewed as an important treatment method in the stabilization of the patient.
Other psychotropic drugs are often prescribed, and polypharmacy is a common method of treatment, as Zink, Englisch, and Meyer-Lindenberg (2010) show in their review of treatment options for schizophrenic patients. The purpose of polypharmacy is to address issues of cognitive disturbance, comorbidity, obsessive-compulsive syndromes, and other side effects that stem from antipsychotic treatment. As their study shows, "the add-on of lithium and mood stabilizers lacks compelling evidence, but might be beneficial for specific subgroups" and "for treatment-resistant cognitive symptoms, antipsychotic medication should be combined with cognitive remediation, as no pharmacological add-on strategy has gained convincing evidence so far" (Zink et al., 2010, p. 103).
In the early stages of treatment, the patient may need to be hospitalized and even restrained to prevent self-injury or injury to others. As Saks (2009) has shown, this type of treatment, while necessary in the short term, can cause long-term negative consequences and prevent the patient from wanting to seek treatment later on, as the memories of being restrained against one's will can be traumatic and cause the patient to want to avoid hospitals and doctors. Saks (2009) recommends that patients be consulted once stabilized regarding how they would like to be treated in the future, should they ever present in a condition where they are unable to function or respond clearly to questions or commands. By giving patients a say — while stable — about whether they would like to be forcefully restrained as a precautionary measure in the future, schizophrenic individuals can feel more confident that their rights and personhood will be respected. This is an important consideration when treating individuals suffering from this disease.
Therapies that are often used in treating schizophrenic patients include cognitive behavioral therapy (CBT), support group therapy, psychoanalysis, and psychosocial therapy. Studies by Turkington, Kingdon, and Turner (2002) show that CBT is an effective way to help stabilize schizophrenic patients in a brief amount of time and can be administered safely by psychiatric nurses to help improve the lives of schizophrenic patients. CBT works effectively because it focuses the patient on adopting behaviors that will counteract the onset of a schizophrenic episode, such as delusional thoughts or hallucinations. It also serves a preventive function by assisting the patient in directing his or her life in a manner that is more conducive to managing the reality of schizophrenia.
Conclusion
Schizophrenia is a common mental disorder that impacts more than 20 million people around the world. It is characterized by symptoms of hallucinations, disordered and confused thoughts and speech, delusions, and a loss of functionality. There is no known cause of schizophrenia and no known cure. However, the symptoms of schizophrenia can be treated so that the individual can lead a relatively normal and productive life. The treatment methods are diverse but typically include some combination of pharmacological agents and therapeutic intervention. While neuroleptics and behavioral therapy are the most recommended and preferred treatment options, the actual intervention used should be decided collaboratively by the provider, the patient, and the patient's family, so that there is a shared understanding of the goals and effects that the treatment will have. Forming a consensus on the best treatment to adopt also keeps everyone informed and gives the patient a more secure sense that his or her rights are being respected.
Create your account
Always verify citation format against your institution’s current style guide requirements.